Denver Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Denver Investment Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-12,417	Closed	-$571K	–	503
2016 Q3	$571K	Sell	12,417 -1,116	-8%	-$58.2K	0.03%	319
2016 Q2	$680K	Sell	13,533 -3,000	-18%	-$160K	0.03%	310
2016 Q1	$885K	Sell	16,533 -1,295	-7%	-$76K	0.04%	278
2015 Q4	$1.17M	Sell	17,828 -4,824	-21%	-$298K	0.05%	257
2015 Q3	$1.28M	Sell	22,652 -1,125	-5%	-$72.9K	0.06%	245
2015 Q2	$1.41M	Sell	23,777 -1,800	-7%	-$111K	0.05%	248
2015 Q1	$1.59M	Sell	25,577 -431	-2%	-$25.1K	0.05%	303
2014 Q4	$1.5M	Buy	26,008 +1,600	+7%	+$89.1K	0.05%	318
2014 Q3	$1.31M	Sell	24,408 -1,466	-6%	-$77.7K	0.04%	325
2014 Q2	$1.36M	Sell	25,874 -6,849	-21%	-$350K	0.04%	338
2014 Q1	$1.73M	Buy	32,723 +3,514	+12%	+$162K	0.05%	323
2013 Q4	$1.17K	Sell	29,209 -30,750	-51%	-$1.21M	0.03%	360
2013 Q3	$2.27M	Sell	59,959 -1,150	-2%	-$44.9K	0.05%	327
2013 Q2	$2.4M	Buy	+61,109	New	+$2.38M	0.06%	296

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Denver Investment Advisors's TEVA Position: Q4 2016 in Review

Denver Investment Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 12,417 shares — an estimated $571K sold.

Denver Investment Advisors first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $2.4M in Q2 2013. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Denver Investment Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Denver Investment Advisors sold 12,417 Teva Pharmaceuticals shares in Q4 2016, an estimated $571K.
Denver Investment Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Denver Investment Advisors's Teva Pharmaceuticals position peaked at $2.4M in Q2 2013.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Denver Investment Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.